Our future collaboration agreements may limit the areas of research and development that we may pursue, either alone or in collaboration with third parties. Much of the potential revenues from these future collaborations may consist of contingent payments, such as payments for achieving certain development milestones and royalties payable on product sales.
Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.
Share structure
Common
207.7M
Pre-funded warrants
0.0M
Options
10.2M
RSUs
6.6M
Warrants
0.0M
Converts
15.5M
Conv preferred
0.0M
ESPP reserve
—
FDSO
240.0M
Cap table as of 2026-11-02.
Rebuilt November 4, 2026 for the Supernus Pharmaceuticals and Indivior business combination, which closed November 2, 2026 (closing 8-Ks filed November 2, 2026). Indivior was the legal acquirer and was renamed Supernus, Inc.; the combined company trades as SUPN and legacy Supernus Pharmaceuticals was delisted. Each legacy Supernus share converted into 1.5401 shares of the combined company. Basic of 207,724,098 is Indivior's 118,035,272 shares at October 9, 2026 (Q3 10-Q cover) plus 89,688,826 shares issued for legacy Supernus's 58,235,716 shares at October 27, 2026 (Q3 10-Q cover). Options of 10,228,588 are legacy Supernus options assumed at the exchange ratio (6,641,509 outstanding at September 30, 2026). RSUs of 6,621,834 are Indivior restricted and performance awards of 5,378,000 at September 30, 2026 plus legacy Supernus RSUs and PSUs of 807,632 at September 30, 2026 converted at the exchange ratio. Converts of 15,467,750 are Indivior's $500M of 0.625% convertible notes due 2031 at the adjusted conversion rate of 30.9355 shares per $1,000 disclosed November 3, 2026 after the special dividend. Cash of $314.5M is a pro forma estimate on September 30, 2026 balances: Indivior cash of $305.0M plus legacy Supernus cash and marketable securities of $359.5M, minus the $350M of combined cash used to fund the $1.0B special dividend paid to legacy Indivior holders at closing. It is before transaction fees and cash paid in lieu of fractional shares. Debt of $650.0M is the new Citibank term loan drawn at closing to fund the rest of the dividend. Indivior's old term loan was repaid in full earlier in 2026, and the convertible notes are counted in the share count, not in debt. Indivior conditional LTIP awards are not counted separately. Company pro forma financial statements are still to come and will replace these estimates when filed.
Price history
Loading SUPN daily closes…
Loading price history…
Next catalyst
SPN-812 · Now - Nov 24, 2026 Now · Phase 3 · Attention-Deficit/Hyperactivity Disorder
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note One of nine commercial products marketed in the U.S. Indication not stated in the excerpts.
GOCOVRI
Approved · Active
Target NMDA receptor (amantadine)
Indications
Parkinson's disease dyskinesia(Approved)
Status note One of nine commercial products marketed in the U.S. Generic competition permitted beginning June 2029 (or sooner under certain conditions) under settlement agreements. Indication not stated in the excerpts.
Status note One of nine commercial products marketed in the U.S. Indication not stated in the excerpts.
APOKYN
Approved · Active
Target Dopamine receptors (apomorphine)
Indications
Parkinson's disease OFF episodes (acute intermittent treatment)(Approved)
Status note One of nine commercial products marketed in the U.S. Company recognized $54.9M impairment charges on the APOKYN acquired intangible asset in Q2 2026. Indication not stated in the excerpts.
XADAGO
Approved · Active
Target MAO-B
Indications
Parkinson's disease (adjunctive to levodopa/carbidopa)(Approved)
Status note One of nine commercial products marketed in the U.S. Indication not stated in the excerpts.
MYOBLOC
Approved · Active
Target SNARE proteins (botulinum toxin type B)
Indications
Cervical dystonia(Approved)
Chronic sialorrhea(Approved)
Status note One of nine commercial products marketed in the U.S. Indication not stated in the excerpts.
ONAPGO
Approved · Active
Aliases SPN-830
Target Dopamine receptors (apomorphine)
Indications
Parkinson's disease motor fluctuations (subcutaneous infusion)(Approved)
Status note One of nine commercial products marketed in the U.S. FDA approved February 2025; acquired in-process R&D considered complete at approval. Supplier constraints impacted ability to meet demand (announced November 4, 2025). Indication not stated in the excerpts.
ZURZUVAE
Approved · ActiveModality: small molecule
Aliases Zuranolone, SAGE-217
Target GABAA
Partnerships Biogen: co-commercialization of ZURZUVAE in the U.S. (co-exclusive license for SAGE-217 products; Biogen is principal in customer sales; costs shared equally); Shionogi: collaboration for zuranolone in MDD and other indications (Shionogi responsible for clinical development and regulatory filings; royalties and milestones to Supernus); acquired via Sage Therapeutics acquisition (closed July 31, 2025)
Indications
Postpartum depression (PPD)(Approved)
Status note Approved for the treatment of PPD in the U.S.; marketed in the U.S. Company generated $63.0M collaboration revenue (ZURZUVAE) in H1 2026. $20M licensing revenue recognized in H1 2026 on a commercial milestone under the Shionogi collaboration.
SPN-817
Stage not disclosed · Active
Target acetylcholinesterase
Indications
Focal Onset Seizures(Phase 2)
Epilepsy(Phase 2)
Seizures, Epileptic(Phase 2)
Status note Named product candidate with direct R&D program expenses; no indication, stage, modality, or target disclosed in the excerpts.
Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (9 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.